Journal
BIOMARKERS IN MEDICINE
Volume 13, Issue 2, Pages 83-93Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2018-0396
Keywords
breast carcinoma; chemotherapy; decision; invasive lobular carcinoma; Oncotype DX (R); prognostic analysis; recurrence score; risk factor; survival
Categories
Funding
- National Natural Science Foundation of China [81872459, 81803050]
- Natural Science Foundation of Fujian Province [2016J01635]
- Natural Science Foundation of Guangdong Province [2018A030313666]
- Science and Technology Planning Projects of Xiamen Science & Technology Bureau [3502Z20174070]
Ask authors/readers for more resources
Aim: To determine the effect of the 21-gene recurrence score (RS) on outcome and chemotherapy decision in breast invasive lobular carcinoma (ILC). Materials & methods: We included 6467 patients with early stage and estrogen receptor-positive ILC from the Surveillance, epidemiology, and end results database. Results: A total of 9.1, 31.4, and 70.1% of patients with low-, intermediate-, and high-risk RS groups received chemotherapy, respectively. A higher RS was independently associated with poor breast cancer-specific survival, and receipt of chemotherapy was not related to better breast cancer-specific survival in low-, intermediate-, or high-risk RS groups. Conclusion: The 21-gene RS could impact chemotherapy decision making in early-stage ILC. However, adjuvant chemotherapy does not appear to improve outcome in high-risk RS cohort.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available